-+ 0.00%
-+ 0.00%
-+ 0.00%
ResMed (RMD), Why Is The Sleep Health Leader Back In Focus?
Share
Listen to the news

ResMed (RMD) has drawn fresh attention after recent price moves left the stock roughly flat over the past month but ahead over the past 3 months, prompting investors to reassess its longer term performance profile.

Over the past year, momentum in ResMed has cooled, with a year-to-date share price return that is down 2.16%. This is in contrast to the 3-year total shareholder return of 63.08%, which still points to a much stronger historical run than the more recent 1-year total shareholder return, which is down 1.04%.

Scan beyond ResMed and see how other hand-picked healthcare leaders stack up on quality and value in the 38 healthcare AI stocks.

ResMed’s share price has paused after a strong few years, so the key question now is whether to invest at today’s level or wait for a clearer markdown before gaining exposure.

Most Popular Narrative: 10% Undervalued

ResMed’s last close of $239.53 sits below the analyst consensus Narrative fair value of $265.11. This frames the stock as modestly undervalued when those long term forecasts are discounted at 7.52%.

Expansion of the diagnosis and treatment funnel through partnerships with consumer wearables and GLP-1 driven patient flows is bringing more previously undiagnosed sleep apnea patients into the ResMed ecosystem, which can support future device and mask revenue growth.

See why 79 investors see ResMed as 10% undervalued.

Result: Fair Value of $265.11 (UNDERVALUED)

Still, the Astral corrective action and the loss of MatrixCare revenue give ResMed holders two clear overhangs that could challenge this undervaluation story.

Find out about the key risks to this ResMed narrative.

Next Steps

Curious whether the market is being too cautious or just about right on ResMed today? Act fast on your own research and weigh the potential by reviewing the 4 key rewards.

Looking for more ideas beyond ResMed?

If you want to round out your watchlist, use the Simply Wall St Screener to spot fresh ideas before they move and avoid being late to the story.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending